EQS-News: Formycon AG / Key word(s): Regulatory Approval/Market LaunchFYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region11.03.2024 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. In Saudi Arabia, MS Pharma will market the biosimilar under the trade name Ravegza®. FYB201/Ravegza® was developed by Bioeq AG, a joint venture between Formycon AG and Polpharma Biologics Group BV. At the end of 2021, the company entered into an exclusive partnership with MS Pharma for the commercialization of FYB201 in the Middle East and North Africa (MENA) region. This strategic collaboration aims to improve access to ophthalmic treatments in the MENA region.
